Diode Laser Cyclophotocoagulation: Glaucoma Uses and Risks

Diode-laser cyclophotocoagulation is a glaucoma procedure that treats the ciliary body to reduce aqueous-humour production and lower intraocular pressure. It can help selected eyes when pressure is not adequately controlled, but it does not restore optic-nerve damage or guarantee that glaucoma will stop progressing.

Key Points

Cyclophotocoagulation is a group of procedures, not one fixed laser protocol.
Continuous-wave, micropulse and endoscopic techniques deliver energy differently and have different indications and trade-offs.
The treatment target and acceptable risk depend on remaining vision, glaucoma type, previous treatment and the individual eye.
Pressure can remain too high or fall too low, and repeat or additional treatment may be required.
Regular pressure, optic-nerve and visual-function follow-up remains necessary.

Why the Ciliary Body Is Treated

The ciliary body produces aqueous humour, the fluid circulating in the front of the eye. Glaucoma damages the optic nerve, often in association with pressure that is too high for that nerve. Cyclophotocoagulation applies energy to ciliary tissue to reduce fluid production; some techniques may also affect fluid outflow.

Lowering pressure aims to reduce the risk of further damage. It cannot recover vision already lost from glaucoma, and a lower pressure reading alone does not prove that the disease is stable.

When It May Be Considered

An ophthalmologist may consider a cyclodestructive procedure when medicines, laser to the drainage angle or incisional surgery have not provided adequate control, are unsuitable, or carry an unfavourable risk in that eye. It may also be used for a painful eye with very limited visual potential.

Some newer techniques are used earlier in selected eyes with useful vision, but this is not a universal first-line rule. Diagnosis, target pressure, lens status, inflammation, previous surgery, anatomy, medication tolerance and the patient’s priorities all influence the decision.

Continuous-Wave Transscleral Treatment

In transscleral cyclophotocoagulation, a probe delivers diode-laser energy through the sclera without directly viewing the ciliary processes. Continuous-wave treatment creates thermal tissue effects. Probe position, treated area, power and duration are chosen by the surgeon; figures from a publication must not be copied as an individual prescription.

The treatment can lower pressure but can also cause inflammation, pain, bleeding, reduced vision, persistently low pressure, shrinkage of the eye and need for further procedures. Rare, serious complications must be included in consent.

Micropulse Transscleral Treatment

Micropulse treatment alternates energy delivery with rest periods. The aim is to limit continuous heat accumulation, but the word micropulse does not mean risk-free or guaranteed to preserve vision. Technique, total energy and patient selection still matter.

Pressure reduction may be incomplete or temporary. Medicines, retreatment or a different glaucoma operation may still be needed. Comparisons between studies can be misleading because definitions of success, patient groups, devices and follow-up differ.

Endoscopic Cyclophotocoagulation

Endoscopic cyclophotocoagulation uses an intraocular camera and laser probe so the surgeon can see the ciliary processes. It may be performed alone or during another intraocular procedure, including selected cataract operations. Entering the eye introduces risks that differ from a transscleral approach.

Potential complications include inflammation, bleeding, pressure spikes, corneal or retinal problems, macular oedema, infection, reduced vision and need for further surgery. Combining it with cataract surgery requires separate discussion of lens choices and cataract-surgery risks.

Assessment Before Treatment

Assessment can include visual acuity, pressure measurement, corneal thickness, gonioscopy, optic-nerve and retinal examination, visual fields and imaging when possible. The clinician should review glaucoma type and severity, previous operations, current drops, inflammation, anticoagulants, general health and anaesthetic considerations.

Ask why this technique is being recommended over medicines, drainage-angle laser, trabeculectomy, a drainage implant or observation. The answer should relate to the examined eye rather than a generic success percentage.

Anaesthesia and the Procedure

Anaesthesia may involve local drops, an injection around the eye, sedation or general anaesthesia depending on the technique and patient. The treating team determines laser settings and treatment extent. Published device parameters are not safe self-management instructions.

Pain or inflammation can occur despite anaesthesia. Tell the team about allergies, medicines and previous reactions. Do not stop glaucoma drops, anticoagulants or other prescribed medicines unless the responsible clinicians give specific instructions.

Aftercare and Monitoring

Post-procedure drops and glaucoma medicines are individual. Pressure can rise initially or later fall below the intended range, so medicines should only be changed by the treating ophthalmologist. Follow-up frequency depends on pressure, inflammation, symptoms and remaining visual function.

Seek urgent eye care for severe or increasing pain, sudden reduction in vision, marked redness, discharge, a new curtain or shadow, flashes with new floaters, nausea with eye pain, or concerning neurological symptoms. International patients need a named local and destination emergency pathway.

Results and Limitations

Possible benefits include lower pressure, fewer medicines or relief of pressure-related pain. None is assured. The outcome depends on diagnosis, baseline pressure, treatment technique, previous surgery and follow-up duration.

Terms such as advanced, gentle, minimally invasive or safer should not replace quantified, eye-specific consent. Ask how the clinician defines success, what happens if pressure remains high, how low pressure is detected and which further treatment would be available.

Planning Care Through Revitalize

Confirm the ophthalmologist’s full name, registration and glaucoma experience, the contracted facility, exact technique and device, anaesthesia plan, aftercare schedule and responsibility for complications. A remote enquiry cannot establish target pressure or suitability.

Revitalize support can help obtain a named-clinician assessment and itemised care plan. Treatment should proceed only after examination and individual consent.

Independent Patient Information

Frequently Asked Questions

Does cyclophotocoagulation restore sight?

No. Its purpose is pressure control or pain relief, not restoration of optic-nerve damage.

Can glaucoma drops be stopped afterwards?

Only if the treating ophthalmologist changes them after pressure and inflammation checks.

Is micropulse treatment risk-free?

No. It changes energy delivery but can still fail to control pressure or cause complications.

Upcoming UK Meetings